Plain-English translation of NCT07598058 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a registry—a database where people with moderate-to-severe hand eczema share their experiences with standard treatments over time. Researchers will use this information to understand how well these medications work, how safe they are, and what side effects people experience in real-world settings, not just in controlled clinical trials. The goal is to help future patients and doctors make better treatment decisions.
Hand eczema is a chronic condition that significantly impacts people's quality of life, yet we don't have enough real-world information about how well existing treatments actually work over the long term or how they affect different patients. This registry will fill that gap by collecting long-term safety and effectiveness data that can't be captured in shorter clinical trials.
You likely qualify if…
You likely don't qualify if…
You would enroll in the registry when you start a standard hand eczema treatment, then complete questionnaires and share health information electronically through your personal device at regular intervals. The registry will track how your hand eczema responds to the medication, any side effects you experience, and how the treatment affects your daily life over months and years. There are no clinic visits required—everything is done remotely through secure online forms.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United States
Sponsor
CorEvitas
Enrollment target
~2,000 participants
Started
July 2026
Primary completion
December 2099
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chronic Hand Eczema Registry Team
CorEvitas
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.